The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1663
ISSUE 1663
November 14, 2022
Issue 1663
- Drugs for Type 2 Diabetes
- Amivantamab (Rybrevant) for Non-Small Cell Lung Cancer (online only)
- Alpelisib (Vijoice) for PIK3CA-Related Overgrowth Spectrum (online only)
- Ciltacabtagene Autoleucel (Carvykti) for Multiple Myeloma (online only)
- Idecabtagene Vicleucel (Abecma) for Multiple Myeloma (online only)
- Neratinib (Nerlynx) for Metastatic HER2-Positive Breast Cancer (online only)
- A New Indication for Axicabtagene Ciloleucel (Yescarta) (online only)
- Teclistamab-cqyv (Tecvayli) For Multiple Myeloma (online only)
- Lurbinectedin (Zepzelca) for Small-Cell Lung Cancer (online only)
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Drugs for Type 2 Diabetes
November 14, 2022 (Issue: 1663)
Diet, exercise, and weight loss can improve glycemic
control, but almost all patients with type 2 diabetes
require antihyperglycemic drug therapy. Treating to
a target A1C of...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.